EGFR and neoplasm: In conclusion, although osimertinib combined with crizotinib showed dramatic tumor shrinkage both in primary tumor and bone metastasis in EGFR T790M-mutant NSCLC patients with MET amplification, more studies should be performed to confirm the clinical benefit in PFS and overall survival.